Janssen Pharmaceuticals has signed a collaboration agreement with the National Taiwan University (NTU) and the university’s hospital (NTUH) to cooperate on developing new drugs for treating hepatitis B. Despite the high success rate of viral suppression achieved by existing medications, the virus is currently incurable.
Chen Ding-shinn (陳定信), chair professor at National Taiwan University Medical College, said that there are more than 350 million people in the world infected with the hepatitis B virus (HBV), 60 to 70 percent of which are in Asia.
Every year, more than 600 thousand people die as a result of complications such as liver cirrhosis and liver cancer caused by the virus.
“HBV can be transmitted prenatally [from mother to child] or by having contact with an infected person. While less than 3 percent of adults infected with the virus develop chronic hepatitis, more than 90 percent of infected newborns do,” Chen said. “Those who have chronic or persistent hepatitis B are at a high risk of developing liver cirrhosis or liver cancer later in life.”
There are about 2.4 million HBV carriers in Taiwan, Chen said, adding that statistics in 2011 showed that deaths attributable to liver cancer ranked No. 2 on the list of leading causes of death for men and women.
“Eighty percent to 90 percent of liver cancer patients had chronic hepatitis B,” he said.
“However, after Taiwan started vaccinating newborns against HBV in 1984, the number of yearly infections has decreased,” Chen said.
While the nation’s vaccination plan is an effective prevention measure, “having better control over the source of infection is still out of reach. Interferon, an approved medication for treating HBV infections is effective in only one-third of patients, while another treatment, nucleoside analogue therapy, inhibits viral replication without completely eliminating the virus.”
The collaboration is intended to develop a treatment to tackle the disease, Jansen, NTU and NTUH said in a joint statement.
Chen Pei-jer (陳培哲), a professor at the Graduate Institute of Clinical Medicine in NTUH’s Medical College and the principal investigator of the collaboration, said the aim is to “accelerate the development of a new hepatitis B drug by combining the resources uniquely held by the respective partners.”
“NTU has been working in this research field for more than 50 years. NTU’s specialization and experience makes it peerless in the fields of drug research and development,” Chen Pei-jer said.
“Janssen has a large collection of compounds as drug candidates. They need a platform to see whether the candidates are safe and effective,” Chen Pei-jer added.
From the mouse model first established by the NTU research team for assaying anti-viral and immune-modulatory activity — an important indication of HBV eradication — and the woodchuck model, which demonstrates HBV activity most similar to that of human HBV, to recent clinical research, Taiwan has always been a leader in the field of HBV treatment, Chen Pei-jer said, adding that NTU’s research was “a complete line from bench to bedside and back.”
“We are aiming to take the lead in developing a new drug to fully eradicate HBV,” the lead investigator said.
China might accelerate its strategic actions toward Taiwan, the South China Sea and across the first island chain, after the US officially entered a military conflict with Iran, as Beijing would perceive Washington as incapable of fighting a two-front war, a military expert said yesterday. The US’ ongoing conflict with Iran is not merely an act of retaliation or a “delaying tactic,” but a strategic military campaign aimed at dismantling Tehran’s nuclear capabilities and reshaping the regional order in the Middle East, said National Defense University distinguished adjunct lecturer Holmes Liao (廖宏祥), former McDonnell Douglas Aerospace representative in Taiwan. If
ECHOVIRUS 11: The rate of enterovirus infections in northern Taiwan increased last week, with a four-year-old girl developing acute flaccid paralysis, the CDC said Two imported cases of chikungunya fever were reported last week, raising the total this year to 13 cases — the most for the same period in 18 years, the Centers for Disease Control (CDC) said yesterday. The two cases were a Taiwanese and a foreign national who both arrived from Indonesia, CDC Epidemic Intelligence Center Deputy Director Lee Chia-lin (李佳琳) said. The 13 cases reported this year are the most for the same period since chikungunya was added to the list of notifiable communicable diseases in October 2007, she said, adding that all the cases this year were imported, including 11 from
Prosecutors in New Taipei City yesterday indicted 31 individuals affiliated with the Chinese Nationalist Party (KMT) for allegedly forging thousands of signatures in recall campaigns targeting three Democratic Progressive Party (DPP) lawmakers. The indictments stem from investigations launched earlier this year after DPP lawmakers Su Chiao-hui (蘇巧慧) and Lee Kuen-cheng (李坤城) filed criminal complaints accusing campaign organizers of submitting false signatures in recall petitions against them. According to the New Taipei District Prosecutors Office, a total of 2,566 forged recall proposal forms in the initial proposer petition were found during the probe. Among those
The Ma-anshan Nuclear Power Plant’s license has expired and it cannot simply be restarted, the Executive Yuan said today, ahead of national debates on the nuclear power referendum. The No. 2 reactor at the Ma-anshan Nuclear Power Plant in Pingtung County was disconnected from the nation’s power grid and completely shut down on May 17, the day its license expired. The government would prioritize people’s safety and conduct necessary evaluations and checks if there is a need to extend the service life of the reactor, Executive Yuan spokeswoman Michelle Lee (李慧芝) told a news conference. Lee said that the referendum would read: “Do
RSS